Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

This study is testing a combination of two cancer drugs — pembrolizumab (an immunotherapy) and olaparib (a PARP inhibitor that blocks cancer cell DNA repair) — for people with advanced pancreatic cancer whose tumors have specific genetic features that may make them more responsive to these treatments. **You may be eligible if...** - You have been diagnosed with metastatic pancreatic cancer (stage 4) - Your tumor has a specific genetic marker: high mutation burden (TMB > 4), a mismatch repair gene mutation (dMMR), or microsatellite instability (MSI-H) - You have received no more than one prior treatment for unresectable or metastatic pancreatic cancer - You are 18 or older in reasonably good health (ECOG 0 or 1) - Your blood counts, liver, and kidney function are adequate **You may NOT be eligible if...** - Your cancer is still potentially resectable (removable by surgery) - You have active brain metastases - You have active autoimmune disease - You are pregnant or breastfeeding - Your tumor does not have the required genetic features Talk to your doctor to see if this trial is right for you.